209 related articles for article (PubMed ID: 21208852)
1. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
Sartor O; Halstead M; Katz L
Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
3. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.
Doyle-Lindrud S
Clin J Oncol Nurs; 2012 Jun; 16(3):286-91. PubMed ID: 22641321
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Mita AC; Figlin R; Mita MM
Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
[TBL] [Abstract][Full Text] [Related]
5. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
6. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel for the treatment of prostate cancer.
Michielsen DP; Braeckman JG; Denis L
Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
11. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Sartor AO
J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel in metastatic castration-resistant prostate cancer.
Yap TA; Pezaro CJ; de Bono JS
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
[TBL] [Abstract][Full Text] [Related]
16. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
17. Tubulin-targeted agents including docetaxel and cabazitaxel.
Cheetham P; Petrylak DP
Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
20. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Masson S; Bahl A
BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
